Gregory Berk

Gregory I.
Berk is currently a Director at Inflection Biosciences Ltd. and Beyond Cancer, Ltd. He is also a Member of the American Society of Clinical Oncology, Inc. and the American Society of Hematology.
Previously, he served as President, Director & Chief Medical Officer at Sideris Pharmaceuticals, Inc., Medical Director at Network for Medical Communication & Research LLC, Vice President-Global Clinical Development at Abraxis BioScience, Inc., Chief Medical Officer & Senior Vice President at Talon Therapeutics, Inc., and Faculty Member at Cornell University.
He was also Chief Medical Officer at GT Biopharma, Inc., DNIB Unwind, Inc., Intellikine LLC, and Verastem, Inc. Additionally, he served as a Chief Medical Officer at Celularity, Inc. Dr. Berk holds a doctorate degree from Case Western Reserve University and an undergraduate degree from Tulane University (Louisiana).